LDS/Medical Tests/AssureMDx® for Bladder Cancer Diagnosis

AssureMDx® for Bladder Cancer Diagnosis

AssureMDx is a proprietary, noninvasive, urine-based DNA test used to assist in the risk stratification of patients presenting with gross or microscopic hematuria. The assay evaluates a single voided urine sample for six genomic and epigenetic biomarkers associated with urothelial carcinoma: DNA methylation of TWIST1, ONECUT2, and OTX1, and somatic mutations in FGFR3, TERT, and HRAS. Biomarker results are combined with patient age using a validated algorithm to produce a qualitative Positive or Negative risk result. A Positive result identifies patients at increased risk for urothelial carcinoma-including some cancers that cystoscopy alone may miss, such as small or flat lesions-supporting more urgent or intensive urologic follow-up. A Negative result carries a high negative predictive value (>99% across published validation studies), supporting avoidance of unnecessary invasive procedures in patients at low risk.

AssureMDx is referenced in American Urological Association (AUA) guideline materials as a validated urine-based genomic test for evaluation of patients with intermediate-risk microscopic hematuria. The test has not been cleared or approved by the FDA; it is validated and offered as a laboratory-developed test by Vesica Health, Inc.

  • As an aid in early detection and diagnosis of bladder cancer
  • Evaluation of patients with gross or microscopic hematuria to support triage for urologic evaluation

Results are reported qualitatively as Positive or Negative, based on an algorithm combining urinary DNA methylation status (TWIST1, ONECUT2, OTX1), mutation status (FGFR3, TERT, HRAS), and patient age.

Positive Result: Genomic alterations associated with urothelial carcinoma were detected; the patient is at increased risk for bladder cancer, and referral for cystoscopy/urologic evaluation is recommended.

Negative Result: No significant genomic alterations detected; associated with a high negative predictive value (>99% in validation studies), supporting a lower likelihood of urothelial carcinoma.

Negative

Methylation-specific PCR and next-generation sequencing (NGS) are used to assess DNA methylation status (TWIST1, ONECUT2, OTX1) and somatic mutation status (FGFR3, TERT, HRAS) in urinary exfoliated cell DNA. Biomarker results are integrated with patient age via a validated predictive algorithm to generate the final Positive/Negative result.

A standard voided urine sample is collected using the collection container supplied in the AssureMDx test kit; no special preparation is required. The sample should be shipped to the laboratory the same day it is collected, using the prepaid mailer included in the kit, per the manufacturer's collection and shipping instructions.

A Positive result should prompt cystoscopy and urologic evaluation. AssureMDx is a triage/risk-stratification test and does not replace cystoscopy as the diagnostic standard for bladder cancer. 

1-2 weeks. 

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login